Biesterfeld Petroplas growing Solvay portfolio helps fight against Covid-19

Written by: Biesterfeld Petroplas Ltd | Published:

In response to COVID-19, the global healthcare community is being challenged to increase the supply of life-saving devices at an unprecedented rate. Biesterfeld Petroplas is here to help. In partnership with Solvay, the industry leader in specialty polymers, we have medical-grade materials available that can be repeatedly disinfected and sterilised.

Solvay’s medical-grade range of Polysulfone resins are ISO 10993 biocompatible and can be used to produce transparent, sterilisable components for ventilators such as connectors, vessels and chambers, that are suitable for patient contact. Udel® PSU, Veradel® PESU, and Radel® PPSU grades are characterised by their high durability and strength combined with strong resistance to chemical cleaners and disinfectants. They are sterilisable by EtO, hydrogen peroxide, gamma radiation and steam. Radel® PPSU can withstand more than 1000 steam sterilisation cycles at 134C.

Also replacing metal with Ixef® PARA helps hospitals and healthcare networks minimise the transfer of infection and reduce central service costs associated with the sterilisation of reusable instruments. ISO10993 biocompatible Ixef® HC-1022 and GS-1022 compounded colours show no significant change in appearance or loss of mechanical properties after exposure to gamma radiation

Solvay’s Tecnoflon® PFR FFKM grades are used to produce high performance rubber parts such as O-rings and pistons for medical equipment. Parts made with Tecnoflon® PFR FFKMs provide safe and long-lasting service even when in contact with oxygen gas, alcohols, hydrogen peroxide, chlorine solutions, as well as sterilizing media such as steam, UV or ozone.


This material is protected by MA Business copyright see Terms and Conditions.
One-off usage is permitted but bulk copying is not. For multiple copies contact the sales team.


Related Content

Websites


Companies

Biesterfeld Petroplas Ltd
Comments
Name
 
Email
 
Comments
 

Please view our Terms and Conditions before leaving a comment.

Change the CAPTCHA codeSpeak the CAPTCHA code